Biosimilar infliximab: short-term efficacy and safety following switch from originator

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Presentation
  • By: MATULUKO, Ayodeji (University College London, School of Pharmacy, London, UK)
  • Co-author(s): Ayodeji Benedicta Matuluko: School of Pharmacy, University College London, United Kingdom
    Natalie Bidad: Department of Practice and Policy, School of Pharmacy, University College London, United Kingdom
    Scott Mercer: Immunotherapy (Rheumatology, Dermatology, Allergy), Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
  • Abstract:

    Methods

    A retrospective/prospective evaluation with a convenience sample of 28 adults who had switched from originator to biosimilar infliximab, was conducted in a rheumatology clinic in London, United Kingdom. Data from patients’ records was collected from May to July 2016, including demographic characteristics, markers of clinical response and

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login